Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers

Pharmacology Biochemistry and Behavior

Volumn 131, Issue , 2015, Pages 119-129

  Knott, Verner ^a,b   De La Salle, Sara ^b   Choueiry, Joelle ^b   Impey, Danielle ^b   Smith, Dylan ^b   Smith, Meaghan ^b   Beaudry, Elise ^b   Saghir, Salman ^b   Ilivitsky, Vadim ^b   Labelle, Alain ^b  

^a ROYAL OTTAWA HOSPITAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Alpha 7 nicotinic receptors; CDP choline; Cognition; CogState battery; Healthy volunteers; Performance

Indexed keywords

CITICOLINE; CHOLINE; NOOTROPIC AGENT;

ARTICLE; ASSESSMENT OF HUMANS; BLOOD PRESSURE; COGNITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; EXECUTIVE FUNCTION; HEART RATE; HUMAN; LEARNING; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECALL; RECEPTOR DOWN REGULATION; TASK PERFORMANCE; TREATMENT RESPONSE; TWO BACK MEMORY PERFORMANCE SCORE; VERBAL MEMORY; WORKING MEMORY; ADOLESCENT; ADULT; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; NEUROPSYCHOLOGICAL TEST; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; CHOLINE; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; YOUNG ADULT;

EID: 84923231071     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2015.02.004     Document Type: Article

References (171)

1. C. Adams, and K. Stevens Evidence for a role of nicotine acetylcholine receptors in schizophrenia Front Biosci 12 2007 4755 4772
2. J. Agut, E. Font, A. Sacristan, and J. Oritz Bioavailability of methyl-14C CDP-choline by oral route Arzneimitteforichong 33 1983 1045 1047
3. C. AhnAllen The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia Curr Opin Psychiatry 25 2012 103 108
4. E. Albuquerque, E. Pereira, M. Braga, and M. Alkondon Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of alpha 7 receptors J Physiol 92 1998 309 316
5. E. Albuquerque, E. Pereira, A. Mike, H. Eisenburg, A. Maelicke, and M. Alkondon Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical evidence Behav Brain Res 113 2000 131 141
6. M. Albus, W. Hubmann, J. Scherer, B. Dreikhorn, S. Hecht, and M. Sobizack A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia Eur Arch Psychiatry Clin Neurosci 252 2002 262 267
7. M. Alkondon, and E. Albuquerque Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons: 1. Pharmacological and functional evidence for distinct structural subtypes J Pharmacol Exp Ther 265 1993 1455 1473
8. M. Alkondon, and E. Albuquerque Subtype-specific inhibition of nicotinic acetylcholine receptors by choline: a regulatory pathway J Pharmacol Exp Ther 318 2006 268 275
9. M. Alkondon, E. Pereira, W. Cortes, A. Maelicke, and E. Albuquerque Choline is a selective agonist of α7 nicotinic acetylcholine receptors in the rat brain neurons Eur J Neurosci 9 1997 2734 2742
10. M. Alkondon, E. Pereira, H. Eisenberg, and E. Albuquerque Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CAI interneurons on rat hippocampal slices J Neurosci 19 1999 2693 2705
11. D. Allen, G. Goldstein, and E. Warnick A consideration of neuropsychologically normal schizophrenia J Int Neuropsychol Soc 9 2003 56 63
12. J. Alvarez-Sabin, and G. Roman Citicoline in vascular cognitive impairment and vascular dementia after stroke Stroke 42 2011 S40 S43
13. J. Arnaiz-Cot, J. Gonzalez, M. Sobrada, P. Baldelli, E. Carbone, and L. Gandía Allosteric modulation of α7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission Eur J Neurosci 27 2008 1097 1110
14. S. Babb, K. Appelmans, P. Renshaw, R. Wurtman, and B. Cohen Differential effect of CDP-choline on brain cystolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy Psychopharmacology 127 1996 88 94
15. M. Bencherif, M. Stachowlak, A. Kuciaski, and P. Lippiello Alpha-7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia Med Hypotheses 78 2012 594 600
16. P. Bentley, J. Driver, and R. Dolan Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging Prog Neurobiol 94 2011 360 388
17. A. Berry, E. Demeter, S. Sabhapathay, B. English, R. Blakely, and M. Sarter Disposed to distraction: genetic variation in the cholinergic system influences distractibility but not time-on-task effects J Cogn Neurosci 26 2014 1981 1991
18. D. Braff, R. Freedman, M. Schork, and I. Gattesman Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder Schizophr Bull 33 2007 21 32
19. A. Breier Developing drugs for cognitive impairment in schizophrenia Schizophr Bull 31 2005 816 822
20. W. Brewer, S. Wood, and I. Phillips Generalized and specific performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis Schizophr Bull 32 2006 538 555
21. J. Buccafusco, J. Brach, and A. Terry Desensitization of nicotinic acetylcholine receptors as a strategy for drug development J Pharmacol Exp Ther 328 2009 364 370
22. R. Buchanan, and R. Schwarcz α7 nicotinic agonists as cognitive treatments: is less (or less often) more? Biol Psychiatry 09 2011 9-6
23. R. Buchanan, R. Keefe, D. Umbrecht, M.F. Green, T. Laughren, and S.R. Marder The FDA-NIMH-MATRICS Guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 37 2011 1209 1217
24. J. Bustillo, L. Rowland, J. Lauriello, H. Petropoulos, R. Hammond, and B. Hart High choline concentrations in the caudate nucleus in antipsychotic-naïve patients with schizophrenia Am J Psychiatry 159 2002 130 133
25. S. Castner, G. Smagin, T. Piser, Y. Wang, J.S. Smith, and E.P. Christian Immediate and sustained improvement in working memory after selective stimulation of α7 nicotinic acetylcholine receptors Biol Psychiatry 69 2011 12 18
26. A. Chen, D. Oathes, C.V. Chang, T. Bradley, Z. Zhou, and L. Williams Causal interactions between fronto-parietal central executive and default-mode networks in humans Proc Natl Acad Sci U S A 110 2013 19944 19949
27. R. Cho, J. Ford, J. Krystal, M. Larvelle, B. Cuthbert, and C. Carter Functional neuroimaging and electrophysiological biomarkers for clinical trials for cognition in schizophrenia Schizophr Bull 31 2005 865 869
28. A. Collie, A. Dareker, G. Weissgerber, M. Toh, P. Snyder, and P. Maruff Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study Contemp Clin Trials 28 2007 391 400
29. R. Conant, and A. Schauss Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature Altern Med Rev 19 2004 17 31
30. A. Cotroneo, A. Castagna, S. Putignano, R. Lacava, F. Fanto, and F. Monteleone Effectiveness and safety of citicoline in mild vascular cognitive impairments the IDEALE study Clin Int Aging 1 2013 131.132
31. J. Coutcher, G. Cawley, and L. Wecker Dietary choline supplementation increases the density of nicotine binding sites in rat brain J Pharmacol Exp Ther 262 1992 1128 1132
32. K. Cropsey, G. Eldridge, M. Weiver, G. Villalobes, and M. Stitzer Expired carbon monoxide levels in self-reported smokers and nonsmokers in prison Nic Tob Res 8 2006 657 659
33. A. Davalos, J. Alvarez-Sabin, J. Castillo, E. Díez-Tejedor, J. Ferro, and E. Martínez-Vila Citicoline in the treatment of acute ischaemic stroke: an international, randomized, multicentre, placebo-controlled study (ICTUS Trial) Lancet 380 2012 349 357
34. S. de la Salle, D. Smith, J. Choueiry, D. Impey, T. Philippe, and H. Dort Effects of COMT genotype on sensory gating and its modulation by nicotine: differences in low and high P50 suppressors Neuroscience 147-156 2013
35. S. Deutsch, B. Schwartz, N. Schooler, C.H. Brown, R.B. Rosse, and S.M. Rosse Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy Schizophr Res 148 2013 138 144
36. D. Dickinson, M. Ramsey, and J. Gold Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia Arch Gen Psychiatry 84 2007 533 542
37. B. English, M. Hahn, and I. Gizer Choline transporter gene variation is associated with activation-deficit hyperactivity disorder J Neurodevelop Disorder 1 2009 252 263
38. D. Evans, and D. Drobes Nicotinic self-medication of cognitive-attentional processing Addict Biol 14 2009 32 42
39. M. Falleti, P. Maruff, Collie, and D. Darby Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one-week and one month test-retest intervals J Clin Exp Neuropsychol 28 2006 1095 1112
40. J. Fan, N.B. McCaudliss, T. Sommer, A. Raz, and M. Posner Testing the efficiency and independence of attentional networks J Cogn Neurosci 14 2002 340 347
41. D. Fayuk, and J. Yakel Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CAI interneurons Mol Pharmacol 66 2004 658 666
42. D. Feifel, F. Macdonald, P. Cobb, and A. Minassian Adjunctive intranasal Oxytocin improves verbal memory in people with schizophrenia Schiophr Res 139 2012 207 210
43. M. Fioravanti, and A. Buckley Citicoline (Cognizin) in the treatment of cognitive impairment Clin Int Aging 1 2006 247 251
44. M. Fioravanti, V. Bianchi, and M. Cinti Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence BMC Psychiatry 92 2012 64
45. R. Freedman α7-Nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia Annu Rev Med 65 2014 245 261
46. R. Freedman, A. Olincy, R. Ross, M. Waldo, K. Stevens, and L. Adler The genetics of sensory gating deficits in schizophrenia Curr Pyschiatry 3 2003 155 161
47. R. Freedman, H. Olincy, R. Buchanan, J.G. Harris, J.M. Gold, and L. Johnson Initial phase 2 trial of a nicotinic agonist in schizophrenia Am J Psychiatry 165 2008 1040 1047
48. T. Fujimoto, T. Nakano, T. Jakano, K. Takeuchi, K. Yamada, and T. Fukazako Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia Biol Psychiatry 40 1996 14 18
49. V. Gallai, G. Mazzotta, C. Firenze, S. Montesi, and F. Del Gatto Study of the P300 and cerebral maps in subjects with multi-infarct dementia treated with cytidine Psychopharmacology 103 1991 1 5
50. R. Garcia-Cobos, A. Frank-Garcia, M. Gutirrez-Fernandez, and E. Díez-Tejedor Citicoline, use in cognitive decline: vascular and degenerative J Neurol Sci 299 2010 188 192
51. H. Geerts α7 nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease Expert Opin Invest Drugs 21 2012 59 65
52. J.-G. Gehricke, S. Loughlin, C. Whaten, S. Potkin, J. Fallon, and L. Jammer Smoking to self-medicate attentional and emotional dysfunctions Nic Tob Res 9 2007 S523 S536
53. J. Gray, and B. Roth Molecular targets for treating cognitive dysfunction in schizophrenia Schizophr Bull 33 2007 1100 1119
54. R. Gray, A. Rajan, K. Radcliffe, M. Yakehira, and J. Dani Hippocampal synaptic transmission enhanced by low concentrations of nicotine Nature 383 1996 713 716
55. M. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153 1996 321 330
56. M. Green, R. Kern, D. Braff, and J. Miurtz Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26 2000 119 136
57. M. Green, R. Kern, and R. Heaton Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS Schizophr Res 72 2004 41 51
58. M. Guseva, D. Hopkins, and J. Pauly An autoradiographic analysis of rat brain nicotinic receptor plasticity following dietary choline modification Pharmacol Biochem Behav 84 2006 26 34
59. B. Hahn, M. Shoaib, and J. Stolerman Nicotine-induced enhancement of attention in five-choice serial reaction time task: the influence of task demands Psychopharmacology 162 2002 129 137
60. P. Harvey, and R. Keefe Studies of cognitive change in patients with schizophrenic following novel antipsychotic treatment Am J Psychiatry 158 2001 176 184
61. P. Harvey, C. Siu, J. Hsu, J. Cucahiaro, P. Maruff, and A. Loebel Effect of Lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and lecture-controlled study followed by a 6-month double-blind extension Eur Neuropsychopharmacol 23 2013 1373 1382
62. D. Haubrich, and B. Pflueger Choline administration: central effect mediated by stimulation of acetylcholine synthesis Life Sci 24 1979 1083 1090
63. S. Heishman, B. Kleykamp, and E. Singleton Meta-analysis of acute effects of nicotine and smoking in human performance Psychopharmacology 210 2010 453 469
64. R. Hurst, H. Rollema, and D. Bertrand Nicotinic acetylcholine receptors: from basic science to therapeutics Pharmacol Ther 137 2012 22 54
65. L. Jarskog, Z. Doug, A. Kangarlu, T. Colibazzi, R.R. Girgis, and L.S. Kegeles Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia Neuropsychopharmacology 38 2013 1245 1252
66. S. Jilka, G. Scott, T. Ham, A. Pickering, V. Bonnelle, and R. Braga Damage to the salience network and interactions with the default mode network J Neurosci 34 2014 10798 10807
67. R. Keefe, R. Bilder, S. Davis, P. Harvey, B. Palmer, and J. Gold Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Arch Gen Psychiatry 64 2007 633 647
68. J. Keller, A. Keller, B. Bowers, and J. Wehner Performance of α7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task Behav Brain Res 162 2005 143 152
69. S. Keri, and Z. Janka Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia Acta Psychiatr Scand 110 2004 83 91
70. R. Kern, K. Nuechterlein, M. Green, L.E. Baade, W.S. Fenton, and J.M. Gold The MATRICS Consensus Cognitive Battery, Part 2: co-norming and standardization Am J Psychiatry 165 2008 214 220
71. J. Klein, A. Koppen, K. Loffelholz, and J. Schmittenner Uptake and metabolism of choline by rat brain after acute choline administration J Neurochem 58 1992 870 876
72. V. Knott, D. Fisher, and A. Millar Differential effects of nicotine on P50 amplitude, its gating, and their neural source in low and high suppressors Neuroscience 120 2010 816 826
73. V. Knott, S. de la Salle, D. Smith, T. Phillipe, H. Dort, and J. Choueiry Baseline dependency of nicotine; sensory gating actions: similarities and differences in low, medium and high Pt0 suppressors J Psychopharmacol 27 2013 790 800
74. V. Knott, J. Choueiry, H. Dort, D. Smith, D. Impey, and S. de la Salle Baseline-dependent modulating effects of nicotine on voluntary and involuntary attention measured with brain event-related P3 potentials Pharmacol Biochem Behav 122 2014 107 117
75. V. Knott, D. Smith, S. de la Salle, D. Impey, J. Choueiry, and E. Beaudry CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression J Psychopharmacol 28 2014 1095 1108
76. K. Koike, K. Hashimoto, N. Takai, E. Shimizu, N. Komatsu, and H. Watanabe Tropisetron improves deficits in auditory P50 suppression in schizophrenia Schizophr Res 76 2005 67 72
77. M. Kraguljac, M. Reid, D. White, R. Jones, J. den Hollander, and D. Lowman Neurometaboites in schizophrenia and bipolar disorder - a systematic review and meta-analysis Psychiatry Res 203 2012 111 125
78. V. Kumari, and P. Postma Nicotine use in schizophrenia: the self-medication hypothesis Neurosci Biobehav Rev 29 2005 1021 1034
79. K. Laffelholz Receptor regulation of choline phospholipid hydrolysin, a novel source of diacylglycerol and phosphatidic acid Biochem Pharmacol 38 1989 1543 1549
80. C. Le Magueresse, V. Safulina, J. Changeux, and E. Cherubiani Nicotinic modulation of network and synaptic transmission in the immature hippocampus investigated with genetically modified mice J Physiol Lond 576 2006 533 546
81. S. Leiser, M. Bowlby, T. Comery, and J. Dunlop A cog-in cognition: low the alpha7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits Pharmacol Ther 122 2009 302 311
82. S. Leonard, S. Mexal, and R. Friedman Smoking, genetics and schizophrenia: evidence for self-medication J Dual Diagn 3 2007 43 59
83. E. Levin Complex relationships of nicotinic receptor actions and cognitive functions Biochem Pharmacol 86 2013 1145 1152
84. E. Levin, and D. Caldwell Low-dose mecamylamine improves learning of rats in the radial-arm maze repeated acquisition procedure Neurobiol Learn Mem 86 2006 117 127
85. E. Levin, S. Briggs, N. Christopher, and J. Rose Chronic nicotinic stimulation and blockade effects on working memory Behav Pharmacol 4 1993 179 182
86. E. Levin, J. Changeux, and C. Mulle Evidence for pretreatment nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus J Neurosci 13 1999 2680 2688
87. E. Levin, M. Cauley, and A. Rezvani Improvement of attentional function with antagonism of nicotinic receptors in female rats Eur J Pharmacol 702 2013 269 274
88. K. Lewandowski, S. Sperry, B. Cohen, and D. Ongur Cognitive variability in psychotic disorders: a cross-diagnostic cluster analysis Psychol Med 44 2014 3239 3248
89. T. Lieberman, G. Dunbar, and A. Segreti A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive impairment in schizophrenia Neuropsychopharmacology 38 2013 968 975
90. S. Luck, D. Mathalon, B. O'Donnell, M. Hamalainen, K. Spencer, and D. Javitt A roadmap for the development of validation of event-related potential biomarkers in schizophrenia research Biol Psychiatry 70 2011 28 34
91. G. Lynch, C. Cox, and C. Galf Pharmacological enhancement of memory cognition in normal subjects Front Syst Neurosci 8 2014 90
92. K. Mackowick, M. Barr, V. Wing, R. Ragin, C. Ouellet-Plamondon, and T. George Neurocognitive endophenotypes on schizophrenia: modulation by nicotinic receptor systems Prog Neuropsychopharmacol Biol Psychiatry 52 2013 79 85
93. T. Madhyastha, M. Askren, P. Boord, and T. Grabowski Dynamic connectivity at rest predicts attention task performance Brain Connect 5 2015 45 59
94. H. Mansvelder, and D. McGhee Long-term potentiation of excitatory inputs to brain reward areas by nicotine Neuron 27 2000 349 357
95. S. Marder The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia Dialog Clin Neurosci 8 2006 109 113
96. L. Martin, and R. Freedman Schizophrenia and the α7 nicotinic acetylcholine receptor Int Rev Neurobiol 78 2007 225 246
97. P. Maruff, E. Thomas, L. Cysique, B. Brew, A. Collie, and P. Snyder Validity of the CogState Brief Battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia and AIDS dementia complex Arch Clin Neuropsychol 24 2009 165 178
98. M. Maxwell Family Interview for Genetic Studies (FIGS): manual for FIGS Clinical neurogenetics branch, intramural research program 1992 National Institute of Mental Health Bethesda MD
99. S. Mexal, P. Jenkins, M. Lautner, F. Jacob, E. Crouch, and J. Stitzel Alpha7 nicotinic receptor gene promoter polymorphisms in inbred mice affect expression on a cell type-specific fashion J Biol Chem 282 2007 13220 13227
100. A. Mike, M. Castro, and E. Albuquerque Choline and acetylcholine have similar kinetic properties of activation and desensitization on the α7 nicotinic receptors in hippocampal neurons Brain Res 882 2000 155 168
101. B. Morley, G. Robinson, G. Brown, G. Kemp, and R. Bradley Effects of dietary choline on nicotinic acetylcholine receptors in brain Nature 266 1977 848 850
102. N. Murthy, H. Mahacke, B. Wexler, P. Maruff, A. Inamdar, and M. Zucchetto Computerized cognitive remediation training for schizophrenia: an open label multi-site multinational methodology study Schizophr Res 139 2012 87 91
103. C. Myers, R. Taylor, B. Salmeron, A. Waters, and S. Heishman Nicotine enhances alerting, but not executive attention in smokers and nonsmokers Nic Tob Res 15 2013 277 281
104. S. Neumann, S. Brown, R. Ferrell, J.D. Flory, S.B. Manuck, and A.R. Hariri Human choline transporter gene variation is associated with corticolimbic reactivity and autonomic-cholinergic function Biol Psychiatry 60 2006 1195-1162
105. P. Newhouse, A. Potter, and A. Singh Effects of nicotinic stimulation on cognitive performance Curr Opin Pharmacol 4 2004 36 46
106. P. Newhouse, A. Singh, and A. Potter Nicotine and nicotinic receptor involvement in neuropsychiatric disorders Curr Top Med Chem 4 2004 267 282
107. P. Newhouse, A. Potter, J. Dumas, and C. Thiel Functional brain imaging of nicotinic effects in higher cognitive processes Biochem Pharmacol 82 2011 943 951
108. K. Nuechterlein, M. Green, R. Kern, L. Baade, D. Barch, and J. Cohen The MATRICS Consensus Cognitive Battery, Part 1: test selection, reliability and validity Am J Psychiatry 165 2008 203 213
109. K. Nuechterlein, J. Ventura, K. Subotnik, and G. Bartzokis The early longitudinal course of cognitive deficits in schizophrenia J Clin Psychiatry 75 Suppl 2 2014 25 29
110. E. Ochoa, and J. Lassalde-Dominicci Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking Cell Mol Neurobiol 27 2007 609 639
111. A. Olincy, and R. Freedman Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor Handb Exp Pharmacol 213 2012 211 232
112. A. Olincy, and K. Stevens Treating schizophrenia symptoms with an α7 nicotinic agonist, from mix to menu Biochem Pharmacol 74 2007 1192 1203
113. A. Olincy, J. Harris, L. Jahnsen, V. Pender, S. Kongs, and D. Allensworth Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia Arch Gen Psychiatry 63 2006 630 638
114. Y. Ouchi, and M. Kikuchi A review of the default mode network in aging and dementia based on molecular imaging Rev Neurosci 23 2012 263 268
115. B. Palmer, R. Heaton, J. Paulsen, J. Kuck, D. Braff, and M. Harris Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 11 1997 437 446
116. G. Paolone, C. Mallory, A. Cherian, T. Miller, R. Blakely, and M. Sarter Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits Neuropharmacology 75 2013 274 285
117. R. Papke, M. Bencherif, and P. Lippiello An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective in the α7 subtype Neurosci Litt 213 1996 201 204
118. E. Pereira, C. Hilmes, M. Santos, M. Alkondon, A. Maelicke, and E. Albuquerque Unconventional ligands and modulators of nicotinic receptors J Neurobiol 53 2002 479 500
119. K. Perkins Baseline-dependency of nicotine effects: a review Behav Pharmcol 10 1999 595 615
120. M. Picciotto, N. Addy, Y. Mineur, and D. Brunzell It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviours related to nicotine addiction and mood Prog Neurobiol 84 2008 329 342
121. R. Pietrzak, J. Olver, T. Norman, D. Piskulic, P. Maruff, and P.J. Snyder A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia J Clin Exp Neuropsychol 31 2009 848 859
122. R. Poorthuis, and H. Mansvelder Nicotinic acetylcholine receptors controlling attention: behaviour, circuits and sensitivity to disruption by nicotine Biochem Pharmacol 86 2013 1089 1098
123. M. Posner, and M. Rothbart Research on attention networks as a model for the integration of psychological science Annu Rev Psychol 58 2007 1 23
124. H. Potter, K. Ryan, and P. Newhouse Effects of acute ultra-low dose mecamylamine on continuation in adult attention-deficit/hyperactivity disorder (ADHD) Hum Psychopharmacol Clin Exp 24 2009 309 317
125. P. Premkumar, V. Parkhakur, D. Fanmnon, D. Lythgoe, S.C. Williams, and E. Kuipers N-acetyl aspartate concentration in the anterior cingulate cortex in patients with schizophrenia: a study of clinical and neuropsychological correlates and preliminary exploration of cognitive behaviour therapy effects Psychiatry Res 282 2010 251 260
126. S. Preskorn, M. Gawryl, N. Dyatlock, M. Palfreyman, L. Bauer, and D. Hilt Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia J Psychiatr Res 20 2014 12 24
127. J. Prickaerts, M. van Goethem, R. Chesworth, G. Shapiro, F.G. Boess, and C. Methfessel EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic receptors Neuropsychopharmacology 62 2012 1099 1110
128. E. Proulx, M. Piva, M. Tian, C. Bailey, and E. Lambe Nicotinic acetylcholine receptors in attention circuitry: the role of layer VI neurons of prefrontal cortex Cell Mol Sci 71 2014 1225 1244
129. A. Rezvani, M. Cauley, and H. Sexton Sazetidine A, a selective α4β2 nicotinic acetylcholine receptor desensitizing agent reverse dizocilpine and scopolamine-induced attentional impairments in rats Neuropsychopharmacology 215 2011 621 630
130. A. Rezvani, M. Cauley, and Y. Xiao Effects of chronic sazetidine-A, a selective β2 nicotinic receptor desensitizing agent on pharmacologically-induced impaired sustained attention in rats Neuropsychopharmacology 222 2012 269 276
131. M. Sarter, and V. Parikh Cholinergic transporters, cholinergic transmission and cognition Nat Rev 6 2005 48 56
132. M. Sarter, W. Behring, and R. Kozak More attention must be paid: the neurobiology of attentional effort Brain Res Rev 51 2006 145 160
133. J. Saver Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair Rev Neurol Dis 5 2008 167 177
134. B. Seaton, G. Goldstein, and D. Allen Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning Neuropsychol Rev 11 2001 45 67
135. J. Secades Citicoline: pharmacological and clinical review, 2010 update Rev Neurol 52 Suppl. 2 2011 S1 S62
136. J. Secades Probable role of citicoline in stroke rehabilitation: a review of literature Rev Neurol Dis 54 2012 173 179
137. J. Secades, and J. Lorenzo Citicoline: pharmacological and clinical review, 2006 update Methods Find Exp Clin Pharmacol 2006 1 56 Suppl. B
138. A. Shiina, Y. Shirayama, T. Niitsu, T. Hashimoto, T. Yoshida, and T. Hasegawa A randomized, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia Ann Gen Psychiatry 9 2010 27
139. A. Simon, K. Cattapan-Ludewig, and S. Zmilacher Cognitive functioning in the schizophrenia prodrome Schizophr Bull 33 2007 761 771
140. J. Simosky, K. Stevens, and R. Freedman Nicotinic agonists and psychosis Curr Drug Targets CNS Neurol Disord 1 2002 149 162
141. N. Sitaram, H. Weingartner, E. Caine, and C. Gillin Choline: selective enhancement of serial learning and encoding of low imagery words in man Life Sci 22 1978 1555 1560
142. B. Snyder, M. Bednar, J. Cromer, and P. Maruff Reversal of scopolamine-induced deficits with a single dose of Donepezil, an acetylcholinesterase inhibitor Alzheimers Dement. 1 2005 126 135
143. R. Steen, R. Hamer, and J. Lieberman Measurement of brain metabolites by H Magnetic Resonance Spectroscopy in patients with schizophrenia: a systematic review and meta-analyses Neuropsychopharmacology 30 2005 1949 1962
144. K. Stevens, and K. Wear Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models Pharmacol Biochem Behav 57 1997 869 874
145. K. Stevens, R. Freedman, A. Collins, M. Hall, S. Leonard, and M. Marks Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains Neuropsychopharmacology 15 1996 152 162
146. A. Szule, B. Galinska-Skok, and E. Tarason Clinical and cognitive correlates of the proton magnetic resonance spectroscopy measures in chronic schizophrenia: clinical features and conceptualization Med Sci Monit 18 2012 CR390 CR398
147. M. Thomsen, D. Christensen, H. Hansen, J. Redrobe, and J. Mikkelsen Alpha (7) nicotinic acetylcholine receptor activation prevents behavioural and molecular changes induced by repeated phencyclidine treatment Neuropharmacology 56 2009 1001 1009
148. M. Thomsen, H. Hansen, D. Timmerman, and T. Mikkelsen Cognitive improvement by activation of α7 nicotinic acetylcholine receptors: from animal models to human pathophysiology Curr Pharm Des 16 2010 323 343
149. J. Tregellas, J. Tanabe, D. Rojas, S. Shatti, A. Olincy, and L. Johnson Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia Biol Psychiatry 69 2011 7 11
150. I. Ulus, and R. Wurtman Choline administration: activation of tyrosine hydroxylase in dopaminergic neurons of rat brain Science 194 1976 1060 1061
151. D. Umbricht, R. Keefe, S. Murray, D. Lowe, R. Porter, and G. Garibaldi A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia Neuropsychopharmacology 39 2014 1568 1577
152. W. Vingerhoets, O. Bloeman, G. Bakker, and T. van Amelsvoort Pharmacological interventions for the MATRICS cognitive domains in schizophrenia: what's the evidence? Front Psychiatry 4 2013 1 22
153. T. Wallace, and D. Bertrand Alpha 7 neuronal nicotinic receptors as a drug target in schizophrenia Expert Opin Ther Targets 12 2013 139 155
154. T. Wallace, and D. Bertrand Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex Biochem Pharmacol 85 2013 1713 1720
155. C. Weickert, T. Weickert, A. Pillar, and P. Buckley Biomarkers in schizophrenia: a brief conceptual consideration Dis Markers 36 2013 3 9
156. G. Weiss Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline Life Sci 56 1995 637 660
157. J. Werkheiser, S. Sydserff, S. Hubbs, M. Ding, M. Eisman, and D. Perry Ultra-low exposure to alpha-7 nicotinic acetylcholine receptor partial agonists elicits an improvement on cognition that corresponds with an increase in alpha-7 receptor expression in rodents: implications for low dose clinical efficacy Neuroscience 186 2011 76 87
158. J. Williams, M. Gibbon, M. First, R. Spitzer, M. Davies, and J. Borus The Structured Clinical Interview for the DSM-III-R (SCID-II). Multisite test-retest reliability Arch Gen Psychiatry 49 1992 630 636
159. V. Wing, C. Wass, D. Soh, and I. George A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia Ann NY Acad Sci 1248 2012 89 106
160. G. Winterer Why do patients with schizophrenia smoke? Curr Opin Psychiatry 23 2010 112 119
161. R. Wurtman, M. Regan, I. Ulus, and L. Yu Effect of oral CDP-choline on plasma choline and uridine levels in humans Biochem Pharmacol 60 2000 989 992
162. J. Young, and M. Geyer Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia Biochem Pharmacol 86 2013 1122 1132
163. J. Young, K. Finlayson, C. Spratt, H. Marston, N. Crawford, and J. Kelly Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor Neuropsychopharmacology 29 2004 891 900
164. J. Young, N. Crawford, J. Kelly, L. Kerr, H. Marston, and C. Spratt Impaired attention is central to the cognitive deficits observed in alpha7 deficient mice Eur Neuropsychopharmacol 17 2007 145 155
165. S. Zeisel Choline phospholipids: signal transduction and carcinogenesis FASEB J 7 1993 551 557
166. S. Zeisel Choline: an essential nutrient Nutrition 16 2000 669 671
167. S. Zeisel Choline: needed for normal development of memory J Am Coll Nutr 19 5 Suppl 2000 5285 5315
168. S. Zeisel, and J. Blusztujn Choline and human nutrition Ann Rev Nutr 14 1994 269 296
169. Z. Zhang, S. Vijayaraghaven, and D. Berg Neuronal acetylcholine receptors that bind α-bungaratoxin with high affinity functions as ligand ion channels Neuron 12 1994 117 177
170. X. Zhang, L. Liu, S. Liu, X. Hong, C. Chen da, and M.H. Xiu Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia Am J Psychiatry 169 2012 974 981
171. M. Zink, S. Englisch, and A. Meyer-Lindenberg Polypharmacy in schizophrenia Curr Opin Psychiatry 23 2010 103 111